China’s mRNA Covid Shot-Maker Expects Efficacy Data by Year End
- Walvax starts Covid shot Phase III trials in Indonesia, Mexico
- Trial will also test vaccine’s efficacy against delta variant
This article is for subscribers only.
The company behind China’s first homegrown mRNA Covid-19 vaccine aims to have efficacy data from late-stage testing of the shot before the end of the year, a key step in the nation’s drive to match western use of the cutting-edge technology.
The mRNA candidate, developed by Chinese vaccine maker Walvax Biotechnology Co., Suzhou Abogen Biosciences Co. and researchers from the Chinese military, has received approval from regulators in Indonesia and Mexico to start Phase III testing, Walvax Vice-Chairman Huang Zhen said in an interview.